Results from a PHASE1 study (NCT06023095) investigating Orforglipron (LY3502970) in Chinese participants with Obesity or Overweight were posted on 2026-07-17. The trial, which enrolled 24 participants, primarily assessed safety and tolerability, reporting no serious adverse events (SAEs) considered related to the study drug administration across all groups.

Background

Orforglipron (LY3502970) was investigated for its safety and tolerability in Chinese participants diagnosed with Obesity or Overweight with weight-related comorbidities.

Trial design

The study, identified as NCT06023095, was a PHASE1 trial that enrolled 24 participants with Obesity or Overweight with weight-related comorbidities. The trial's main purpose was to learn about the safety and tolerability of LY3502970 when given to Chinese participants, and to investigate how the body processes the study drug and how it affects the body. Participants received either LY3502970 or placebo orally.

Key results

The study reported on the number of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) considered related to study drug administration. Across all groups, no participants experienced serious adverse events (SAEs) considered related to study drug administration.

The number of participants with one or more TEAEs considered related to study drug administration were:

  • LY3502970 (Cohort 1): 10 participants
  • LY3502970 (Cohort 2): 8 participants
  • Placebo: 3 participants

Pharmacokinetic data for the maximum observed concentration (Cmax) of LY3502970 at steady state were also reported:

  • For LY3502970 (Cohort 1), geometric mean Cmax values were 17.6 ng/mL (Geometric Coefficient of Variation 39) and 61.3 ng/mL (Geometric Coefficient of Variation 43).
  • For LY3502970 (Cohort 2), geometric mean Cmax values were 5.01 ng/mL (Geometric Coefficient of Variation 44), 35.1 ng/mL (Geometric Coefficient of Variation 41), 116 ng/mL (Geometric Coefficient of Variation 42), and 159 ng/mL (Geometric Coefficient of Variation 41).

What this means

The results from this PHASE1 study indicate that Orforglipron demonstrated a tolerable safety profile in Chinese participants with Obesity or Overweight, particularly with the absence of any serious adverse events considered related to the study drug. The presence of treatment-emergent adverse events across dose groups is typical for early-phase trials and helps characterize the drug's safety profile. The pharmacokinetic data provides initial insights into how the body processes LY3502970, which is crucial for further development.

Source

This information was sourced from ClinicalTrials.gov, documenting the results of trial NCT06023095, which were posted on 2026-07-17. The study details are available on clinicaltrials.gov.